BioTissue Announces Strategic Collaboration Agreement with SightLife™ to Provide Cryopreserved Amniotic Membrane Products to Kaiser Permanente Facilities

MIAMI, Fla., August 30, 2016 – BioTissue^®, the industry leader in regenerative tissue therapies and ocular hygiene products for lid margin and ocular surface diseases, is pleased to announce a strategic collaboration agreement with SightLife, a Seattle-based eye bank and the largest provider of corneal tissue for transplant. As part of the agreement, SightLife, which is the preferred supplier of corneal tissue for Kaiser Permanente, will provide BioTissue’s cryopreserved amniotic membrane ocular wound healing products to hospitals and eye clinics in Kaiser Northern California, Southern California and the Pacific Northwest.

“Our collaboration with SightLife will support our efforts to further expand use of our cryopreserved amniotic membrane products within Kaiser Permanente facilities,” said Thomas G. Daniells, Chief Commercial Officer, BioTissue. “SightLife’s expertise and experience working with Kaiser Permanente doctors and hospitals, makes the organization an ideal partner to provide our products to Kaiser facilities for the treatment of ocular surface diseases and conditions.”

As part of the collaboration with BioTissue, SightLife will provide Kaiser facilities with BioTissue’s AmnioGraft^® biologic ocular transplantation graft, AmnioGuard^® biologic glaucoma shunt tube graft, and Prokera^® biologic corneal bandage devices, the only therapeutic devices cleared by the U.S. Food and Drug Administration (FDA) that reduce inflammation and promote regenerative healing of the ocular surface.

SightLife is the largest and most experienced provider of corneas for transplant in the world, and is the only non-profit Global Health Organization and Eye Bank solely focused on eliminating corneal blindness worldwide. SightLife and its global partners provided nearly 24,600 corneas for transplant in 33 countries in 2015.

About BioTissue
BioTissue, Inc. is a subsidiary of TissueTech, Inc., a privately held biotechnology company that develops innovative wound healing and hygiene solutions for the prevention and treatment of ocular surface diseases and disorders. BioTissue provides a comprehensive line
of cryopreserved amniotic membrane ocular wound healing products, including AmnioGraft, a biologic ocular transplantation graft; AmnioGuard, a biologic glaucoma shunt tube graft; and the Prokera family of biologic corneal bandage devices. These products incorporate human amniotic membrane processed with the company’s proprietary CryoTek^® method proven to preserve the biological properties of amniotic membrane and umbilical cord tissue essential for anti-inflammatory and anti-scarring effects compared with the dehydration method that drastically alters the structural and biological integrity of this tissue.1 BioTissue also developed and markets the Cliradex^®line of products, a natural lid, lash and facial cleanser with 4-Terpineol, the active component of tea tree oil (TTO), for the management of symptoms in lid margin diseases such as blepharitis, Demodex, and rosacea. For more information, visit www.biotissue.com.